In the final partial registration with the Swedish Companies Registration Office, which was registered today, 1,611,850 units corresponding to SEK 10,315,840 have been registered with the Swedish Companies Registration Office. Following the final registration of the Rights Issue with the Swedish Companies Registration Office, the Company’s share capital amounts to SEK 4,753,903.10 and the total number of shares in the Company amounts to 47,539,031 shares.
Terms for the warrants of series 2022/2023 (CALMA TO 3 B) in short:
The exercise period for the subscription of B-shares supported by the warrants will run from August 14, 2023, until August 28, 2023.
The subscription price for the subscription of B-shares using warrants will correspond to 75 percent of the volume-weighted average price paid for the Company's B-shares on Spotlight Stock Market during a period of ten (10) trading days prior to August 14, 2023. However, the subscription price cannot be higher than SEK 3.20 and not lower than SEK 1.60. If fully exercised, 3,718,161 new B-shares are issued. This means that upon full subscription, the Company can receive up to approximately SEK 11.9 million (before issue costs), depending on the exercise price, and if all the warrants are exercised for share subscription. Thus, the share capital may increase with a maximum of approximately SEK 371,816.10, which is in total a maximum share capital of approximately SEK 5,125,719.20.
Stockholm Corporate Finance is acting as financial adviser and Moll Wendén Advokatbyrå AB is acting as legal advisors in connection with the Rights Issue. Hagberg & Aneborn Fondkommission AB is the issuing institution in the Rights Issue.
For further information, please contact:
Calmark Sweden AB (publ)
Anna Söderlund, CEO
Tel: +46 70 213 25 35
Calmark Sweden AB is a MedTech company that develops and sells a point-of-care (POC) analysis system for a more time- and cost-efficient diagnostics procedure of common medical conditions in newborns. The unique test platform consists of a portable instrument and test cassettes for various biomarkers. Market launch of the first test, Neo-Bilirubin began in 2020. In developed healthcare systems, the introduction of POC tests leads to large costs savings and shorter healthcare chains. In less developed healthcare systems, Calmark's products offers a support for diagnosis that does not exist today as access to hospital laboratories is often limited. Calmark aims to become a global leader and in the long-term offer all relevant tests for newborns regardless of where in the world they are born. In addition to products for newborns, Calmark also sells a POC test for assessing the severity of covid-19. The B-share is listed on the Spotlight Stock Market and is traded under the name CALMA B. Read more at www.calmark.se
About Stockholm Corporate Finance AB
Stockholm Corporate Finance is a Swedish, independent, and privately-owned financial advisor that offers financial advisory in capital raisings, ownership changes, and mergers and acquisitions to listed and privately held companies. Stockholm Corporate Finance is the exclusive Swedish partner in the global network M&A Worldwide, that consists of 49 M&A-advisors and investment banks in 36 countries. Stockholm Corporate Finance is under the supervision of the Swedish Financial Supervisory Authority, Finansinspektionen, and is a member of SwedSec Licensiering AB. For further information see: www.stockholmcorp.se